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A NEW ALGORITHM FOR THE MANAGEMENT OF DERMATOFIBROSARCOMA 
PROTUBERANS. 
Carolyn Goldberg and Deepak Narayan.  Division of Plastic Surgery, Department of 
Surgery, Yale University School of Medicine, New Haven CT. 
The purpose of this project was to design an algorithm for the management of 
Dermatofibrosarcom Protuberans (DFSP.)  The National Cancer Center Network 
guidelines suggest immediate reconstruction in most cases after DFSP resection.  We 
believe this algorithm is inadequate.  Due to the infiltrating nature of DFSP, tumor 
margins are often positive after resection.  Immediate reconstruction in the context of 
residual tumor is problematic because of the risk for spreading microscopic disease and 
the potential to compromise reconstructive options.  At our institution we examined the 
prevalence of positive margins on permanent pathology after immediate closure 
following surgical resection of DFSP.  Forty-one patients were identified; 25 had 
received treatment with surgical excision and 16 with Mohs surgery.  Of the 25 patients 
that were treated with surgical excision, 20 underwent immediate closure and 5 
underwent delayed closure after tumor resection.  Eight out of 19 (40%) of patients who 
underwent immediate closure were found to have positive margins on permanent 
pathology.  Given these findings, we propose a treatment algorithm focused on more 
conservative surgical management of DFSP in which negative margins are established 
before closure.  Mohs surgery, which allows for immediate identification of pathology, 
plays a central role.   
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INTRODUCTION 
Dermatofibrosarcoma protuberans (DFSP) is a rare, locally invasive soft tissue sarcoma 
with a propensity for extensive subclinical involvement. Originating in the dermal layer 
of skin, microscopic tendrils of tumor may extend far beyond the margin of clinically 
evident tumor. While painless and often indolent appearing, the tumor can grow quite 
large before receiving clinical attention.  Local invasion can include subcutaneous tissue, 
muscle, fascia and bone.  The local recurrence rate is high, in some studies upwards of 
60%, likely reflecting a failure to remove occult extensions of tumor.1  Fortunately, 
distant metastasis is rare (between 1 and 4%) and complete removal is considered 
curative.2 
 The cell of origin for DFSP is controversial.  Several authors theorize that DFSP 
arises from fibroblasts, as tumor cell features that are consistent with modified fibroblasts 
have been observed on electron microscopy.3  In addition, like fibroblasts, DFSP cells 
stain with vimentin and contain active endoplasmic reticulum that readily synthesize 
collagen.4  However, several studies in tissue culture indicate that tumor cells may be 
histiocytes that have acquired fibroblastic elements.  The growth pattern of DFSP 
resembles that of fibroblasts in the body, which serve to support tissue through formation 
of a lattice network around cells.  DFSP cells mimic the fibroblast infiltrative growth 
pattern with pseudopod like extensions from a central mass that penetrate fat and adjacent 
tissue over time.3  It may be that this similarity to the fibroblast growth pattern explains 
the low rate of blood borne metastasis, as fibroblasts tend to remain enmeshed in the area 
they stabilize.5  Histologically, DFSP is characterized by a fibroblastic proliferation of 
tumor cells arranged about a central hub in a storiform pattern.2 (Figure 1) 
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Figure 1.  Microscopic appearance of DFSP  
 
 Ninety percent of DFSP tumor cells exhibit a chromosomal translocation of genes 
COL1A9 and PDGFβ (t17;22,) which encode the alpha chain of type I collagen and the 
beta chain of platelet-derived growth factors, respectively.6  The fusion protein produced 
by this translocation causes continuous stimulation of the PDGF protein tyrosine kinase, 
resulting in increased production of PDGF and abnormal cellular proliferation.7  
Fibrosarcomatous-DFSP is a more aggressive variant of DFSP and likely represents 
dedifferation.  The increased cellularity and mitotic activity observed on histology for 
these tumors are indistinguishable from the cytologic and architectural pattern of a high 
grade fibrosarcoma, and this variant is associated with a higher rate of recurrence and 
metastasis.6,8,9  
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 The development of DFSP may be linked to traumatic wounds, scarring, and 
viruses.  In a retrospective analysis by Yu et al., 24% of patients recalled an antecedent 
trauma at the site of tumor development.10  Green et al. describe a 69-year old who 
presented with a DFSP located at a smallpox vaccination site.11  At least six other 
accounts of DFSP exist in which the tumor developed in a site of prior immunization 
inoculation.11  Persistent inflammation is thought to account in part for the association of 
scars with an increased risk of malignancy.10 
 Historically, surgical excision has been the treatment of choice for the resection of 
DFSP.  However, the ideal width of margins remains undefined.  Parker et al. mapped the 
subclinical tumor extension in 20 patients with Mohs surgery and measured the margins 
required to completely clear the tumor.  A 2.5 cm margin through the deep fascia was 
shown to clear all tumor cells completely, and the tumors measuring less than 2 cm were 
completely cleared with a 1.5cm margin.12  However, other studies have documented 
tumor projections that extend anywhere from 3 to 10 cm beyond the tumor center leading 
to recommendations for margins of up to 5cm.4,13  A review of the literature by Gloster et 
al. found a trend of improving recurrence rates with increasingly wider resection margins.  
The recurrence rate decreased from an average of 43% to 18% in series with wider 
margins (defined as greater than or equal to 2 cm) compared to undefined or more 
conservative margins.2  Even among studies where resection margins were 5 cm, the 
recurrence rate reached 23%.14  Most authors currently suggest a margin of 2 to 3 cm 
with a three dimensional resection including skin, subcutaneous tissue, and the 
underlying investing fascia.8   
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 Several authors have suggested that traditional surgical excision, which removes 
tissue in a concentric ring based on the macroscopic extent of the tumor, is not well 
suited for removal of DFSP.  This surgical approach is predisposed to remove too much 
healthy tissue without eradicating the extensive, asymmetric projections of tumor cells.13  
In the last several decades, Mohs surgery has emerged as a promising treatment option 
that may achieve superior results to surgical excision.15  Mohs surgery provides a method 
of eradicating tumor that rests on intraoperative evaluation of tumor margins.  The tumor 
is resected in a stepwise fashion with tissue removal that is based on the presence of 
tumor cells.  In addition to conserving tissue, the pathologic techniques used in Mohs 
surgery have been shown to provide an excellent rate of cure with very few documented 
recurrences.   
 After resection of DFSP, the National Comprehensive Cancer Network (NCCN) 
guidelines recommend immediate reconstruction in most cases, but state that “it is 
preferable to delay deep undermining or flap reconstruction until negative surgical 
margins are assessed.”16  These recommendations for treatment of DFSP are potentially 
problematic because of the emphasis on clinical judgment for determining whether to 
perform immediate or delayed reconstruction.  It is often difficult to predict the extension 
of the tumor, because of the eccentric pattern of invasion characteristic of DFSP that 
mimics normal tissue.17  Immediate reconstruction can compromise options for 
subsequent surgery if positive margins found on permanent pathology necessitate further 
excision.  In addition, immediate reconstruction in the context of residual tumor may 
pose a risk for the spread of microscopic disease.  For these reasons, we believe the 
current guidelines for the management of DFSP are inadequate. 
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STATEMENT OF PURPOSE 
The purpose of our study is to design an algorithm for the management of DFSP focused 
on establishment of negative margins before closure.  
 
METHODS 
Patients were identified through the surgical pathology and dermatopathology laboratory 
database and stratified by surgical treatment type: surgical excision or Mohs surgery.  
Data was collected retrospectively and entered into de-identified research records. 
 Twenty-one patients were identified in the Yale surgical pathology database as 
having received surgical treatment for DFSP from 1990 to 2009.  We included cases in 
which pathology of a biopsy of the lesion was consistent with DFSP.  All patients who 
underwent surgery for DFSP were included.  Patients were defined as having primary 
disease if they had never received previous treatment for DFSP, and recurrent disease if 
tumors arose at the site of previous resection.  Patients with primary DFSP presented at 
our institution either for initial treatment or after previous inadequate surgery to undergo 
re-excision.  Hospital and clinic outpatient charts were obtained and the following 
information was collected: age at onset, sex, disease state (primary presentation versus 
recurrence), tumor site, type of closure, size of margin, need for local tissue flaps and 
skin grafts in closure, status of margins on permanent pathology, and duration of follow 
up.  We recorded the margin noted in the initial operative report as well as margins taken 
during subsequent resections.  Margin size was missing for two patients.  In addition, we 
recorded whether patients experienced disease recurrence (recurrent tumor after negive 
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pathology following resection) or extension of disease (recurrent tumor after incomplete 
resection.) 
 Twenty patients were identified by the Yale dermatopathology laboratory database 
as having been treated at this institution for DFSP from 1990, when the database was 
created, to 2009.  These patients were stratified by the type of surgical treatment they 
received.  Four patients were treated with surgical excision and 16 patients were treated 
with Mohs surgery.  The patients who received surgical excision were grouped with the 
patients from the Yale surgery pathology database and evaluated for the same factors 
listed above.  Information from the medical charts of the patients who received Mohs 
surgery was collected on tumor site, type of closure performed, number of stages and 
histologic sections during surgery, size of lesion, size of the postoperative defect (defined 
as the wound dimensions recorded in the operative report immediately prior to closure) 
and duration of follow up.  Tumor size or size of postoperative defect was missing for 
two patients. 
 In addition to the above parameters, we wanted to compare the margin size for 
Mohs surgery with the margin size used during surgical excision to determine whether 
Mohs surgery conserved more normal tissue than surgical excision.  Because data on 
excisional margins was not available for Mohs surgery patients, we calculated the 
margins in the following manner: the larger measurement of the preoperative defect size 
was subtracted from the larger measurement of the postoperative tumor size to obtain a 
total margin.  This margin was divided in half based on the assumption that the margin 
was applied circumferentially around the lesion to yield the actual margin.  The smaller 
measurement of the preoperative tumor size was also subtracted from the smaller 
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measurement of the postoperative defect size and divided in half.  The two values were 
averaged to arrive at the excisional margin for each patient.    
 This study was approved by the Yale University Human Investigation Committee 
(HIC#0803003577).   
 
RESULTS 
Forty-one patients were treated for DFSP by surgical excision, Mohs surgery, or a 
combined approach at our institution from 1990-2009. The distribution of lesions is 
summarized in Figure 1.  Overall, the trunk was the most common site for DFSP, 
followed by the head and neck.  No patients had distant metastasis at the time of 
diagnosis.  One patient presented with extension of disease after incomplete resection in 
the surgical excision group.  No patients experienced recurrence (presentation of disease 
after negative surgical margins) in either the surgical excision or the Mohs surgery group.  
The average duration of follow up was 107.9 months for all patients. 
 
Figure 2. Distribution of Lesions 
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Surgical Excision Group (Table 1) 
 Twenty-five patients underwent surgical treatment for removal of DFSP between 
1990 and 2009 by 20 surgeons in the Division of Plastic Surgery, Department of Surgery, 
and Section of Dermatologic Surgery and Cutaneous Oncology in the Department of 
Dermatology.  Excluding two patients for whom the state of disease was not reported 
78.3% of patients presented with primary disease and 34.8% presented with recurrent 
disease.  The age range was 12 to 84 years with a mean age of 46.1 years.  Sixty-eight 
percent of patients were female and 32% were male. 
 Sixty-four percent of the lesions were found on the trunk, 28% were found on the 
head and neck, and the remaining lesions were found on the extremities.  More 
specifically, there were five lesions on the back, four on the shoulder, three on the chest, 
three on the abdomen, and one on the breast.  Two patients had lesions on their lower 
extremities.  In the head and neck region, there were two patients with scalp lesions, two 
patients with lesions on or around the temple, one patient with a lesion over the parotid 
gland, and one patient with a lesion on the posterior neck.  One DFSP lesion was found 
on the eyelid.   
 The average margin size for patients after initial surgical excision was 2.33 cm.  
The narrowest margin taken was .75 cm (for the patient with DFSP of the eyelid) and the 
widest margin was 4.5 cm.  However, the average surgical margin including all 
subsequent surgical resections after permanent pathology was 2.79 cm, with a maximum 
width of 6 cm.  The median margin size was 2.5 cm after initial surgical resection and 3 
cm after including cumulative surgical resections.  Five patients underwent delayed 
closure and 20 patients underwent immediate closure after resection.  Twelve patients 
13 
(48%) were found to have positive margins after initial resection.  The duration of follow 
up ranged from 27 to 105.5 months, with an average of 105.5 months (8.75 years.) 
Delayed Closure (Figure 1) 
  Five patients (20.8%) underwent delayed closure of the wound with planned re-
operation and closure pending the results of permanent pathology.  Two of these patients 
presented to our institution with recurrence, and one patient presented from an outside 
hospital for further resection after positive margins were found on initial resection.  
Allograft was placed on the wound as a temporary dressing for all five of these patients.  
The average time between the first and second surgery was 8.2 days, with a minimum of 
three days and a maximum of 13 days.  Four of the five patients were found to have 
positive permanent pathology necessitating further resection.  All but one patient was 
cleared histologically after a second resection.   
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Figure 3.  Images of a patient treated with delayed reconstruction after resection of DFSP 
of the left chest wall.  A. Gross appearance of lesion.  B. Specimen.  C. A 30 by 20 cm 2 
defect was present after tumor resection.  D. Allograft was used to temporarily close the 
defect.  E. The results of permanent pathology showed tumor extension at the 7-8 o’clock 
margin, with skeletal muscle negative for malignancy.  The patient underwent further 
resection 19 day later, with intraoperative frozen sections of the new margin found to be 
negative.  Closure was performed with Gore-Tex mesh and bilateral external oblique 
myocutaneous flaps.  No malignancy was found on permanent pathology after re-
excision.  E. Photograph from follow up appointment at clinic. 
A.       B. 
 
 
 
 
 
 
 
 
 
 
C.         D. 
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Immediate Closure  
 Twenty patients (80%) underwent immediate closure after surgical resection.  Six 
of the patients who were treated with immediate closure had presented to our institution 
with recurrent disease.  Eleven patients who received immediate closure required local 
flaps for reconstruction.  One patient underwent immediate reconstruction with a radial 
forearm free flap. 
 Eight of the 20 patients (40%) who received immediate closure were found to have 
positive margins on permanent pathology.  Three of these patients had undergone 
reconstruction with local flaps.   
 One patient received combined treatment with surgical resection followed by Mohs 
surgery.  This was a 33 year-old woman who had previously been treated for DFSP of the 
forehead and upper eyelid at an outside hospital.  She presented to the plastic and 
reconstructive surgery clinic at our institution with recurrent disease.  She was treated 
with resection of tumor to the periosteum of bone.  Intraoperatively, frozen sections 
showed negative margins.  After surgery she received immediate reconstruction with a 
split-thickness skin graft.  Permanent margins extending into the upper eyelid were found 
to be positive.  She was referred for Mohs surgery where the resection was completed. 
 One patient in the surgical excision group presented with extension of disease after 
incomplete surgical excision.  This was a 48 year-old female who received immediate 
reconstruction after resection of a large DFSP of the scalp and was found to have positive 
margins on permanent pathology.  The patient was referred for radiation therapy, but 
elected to pursue observation of the lesion only.  Two years later, the patient presented 
with nodules at the edge of the split thickness skin graft found to be DFSP.  She 
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underwent further resection, this time with reconstruction of the defect with a 
fasciocutaneous flap from the posterior cervical muscles.  On permanent pathology, the 
tumor approached within 1 mm at the deep margins.  The patient elected to pursue 
radiation therapy, and has had no recurrences in the four years following treatment. 
Table 1.  Permanent pathology results after surgical excision 
 Number of Patients 
(Percent) 
Positive Margins 
(Percent) 
Negative Margins 
(Percent) 
Immediate Closure 19 (79.2%) 7 (36.8%) 12 (63.2%) 
Delayed Closure 5 (20.8%) 4 (80%) 2 (20%) 
 
 
Mohs Surgery Group (Table 2) 
 Mohs surgery was performed on 16 patients by three dermatologists in the Section 
of Dermatologic Surgery and Cutaneous Oncology in the Department of Dermatology.  
Like the surgical excision group, most lesions (56.3%) were found on the trunk.  A 
greater percentage of lesions were found on the extremities than for surgical excision 
(31.3 vs. 8.0%), and fewer lesions were found on the head and neck (12.5 vs. 28.0%).  
More specifically, there were three lesions on the back, three on the shoulder, two on the 
abdomen, one on the chest, and one on the hip.  Two patients had lesions on the clavicle 
and scalp at the hairline.  Of the five patients with lesions on the extremities, 2 patients 
had lesions on the hand, two on the calf or lower leg, and one on the dorsum of the foot.  
 Thirteen lesions (81.3%) approached initially with Mohs surgery were cleared 
histologically after five stages of Mohs surgery.  Three patients were referred for surgical 
excision because of failure to achieve clear margins with local anesthesia at the time of 
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Mohs surgery.  These patients continued to have one histologic section positive after four 
stages of surgery and out of  9, 12, and 14 total histologic sections.    
 Most patients required several staged Mohs excisions to achieve complete tumor 
clearance.  Thirty-one percent of lesions were excised in a single procedure, 12.5% were 
excised after two stages, 18.8% after three stages, 12.5% after four stages, and 6.3% after 
five stages.  At each stage of resection, multiple histologic sections were required to 
analyze the entire peripheral margin.  Excluding the three patients referred for further 
surgical excision, the average number of histologic sections taken was 8.6.  The 
minimum number of sections was two and the maximum was 19.  
 Of the patients with lesions cleared by Mohs surgery, two patients (15.4%) were 
left to heal by secondary intention, 10 (76.9% ) of the patients underwent complex linear 
closure, and one patient was referred to a plastic surgeon for wound closure.  The average 
margin taken was 1.36 cm, with a median margin width of 1.17 cm.  The maximum 
margin taken was 2.55 and the minimum margin was 0.74 cm. 
 No patient in the Mohs excision group experienced recurrence over a follow-up 
period ranging from 10.5 to 200.5 months, with an average duration of follow-up of 112 
months. 
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Table 2.  Patient Characteristics and Results of Mohs Surgery  
Patient Location Stages Required 
for Clearance 
Total 
Sections 
Closure Type Size of Lesion  
(cm) 
1 L lateral calf 1 4 Secondary 
intention 
1.9 x 2 
2 L dorsal hand 3 5 CLC 0.7 x 0.4 
3 L shoulder 3 23 Delayed* Not reported 
4 L abdomen 2 14 CLC 7 x 1 scar 
5 L deltoid 1 2 CLC 1 x 1.5 
6 L hip 1 4 CLC 0.3 x 2.5 
7 L dorsal hand 5 19 CLC, small area 
left to granulate 
4.8 x 1.7 
8 R lower leg 4 13 Secondary 
intention 
2 x 1 
9 R inf back 2 6 CLC 3 x 2.4 
10 L flank 1 4 CLC 7.6 x 0.3 
11 R ant sup 
Shoulder 
4 12 CLC 0.9 x 0.7 
12 R upper back 3 4 CLC 1.2 x 1.3 
13 R abdomen 1 2 CLC 1.3 x 1.2 
14 R clavicular 
area 
4** 9 CLC* 3 x 1.5 
15 Ant. R scalp at 
hairline 
4** 14 Delayed* 2 x 5 
16 Foot 4** 12 Delayed* 1 x 3 
CLC: Complex linear closure 
**negative margins not achieved with Mohs surgery.  
*patients referred to plastic surgeon for further surgical resection and/ or closure 
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DISCUSSION  
 As mentioned above, the National Comprehensive Cancer Network (NCCN) 
guidelines for management of DFSP recommend immediate closure in most cases, 
although “it is preferable to delay reconstruction involving extensive undermining or 
flaps until negative surgical margins are assessed and certified pathologically clear.”16 
Given the important prognostic relevance of establishing negative margins, we believe 
that reconstruction after tumor resection should be dependent on definitive clearance of 
the tumor.  In light of the difficulty in judging the extent of DFSP, and the potential 
complications of reconstruction after positive margins are found, we feel that the 
treatment guidelines should be more conservative. Although multiple algorithms for the 
treatment of DFSP exist,10,18 few incorporate closure guidelines into the 
recommendations.  Here we present a new algorithm for surgical management of patients 
diagnosed with DFSP focused on the establishment of negative margins before closure 
(Figure 4.)  Mohs surgery, which allows for immediate identification of pathology, plays 
a central role.  Following a description of the algorithm, we will further discuss 
conservative treatment modalities such as Mohs surgery and surgical excision with 
delayed closure.  Finally, we review reconstructive options after resection, and further 
therapy for metastatic DFSP and unresectable DFSP.  
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Figure 4.  
 
 
 
 
The extent of DFSP is difficult to determine intraoperatively with traditional surgical 
excision, leading to a high rate of positive microscopic margins.  In our analysis, nearly 
half of all patients (48%) had positive margins after initial tumor resection, despite wide 
surgical margins (median initial resection margin was 2.5 cm) that fell well within the 
accepted wide excision widths in the literature.8  Rearrangement of tissue during closure 
may disseminate residual tumor cells, making re-resection of the positive margin 
inadequate to remove all disease.  Resection with delayed closure ensures that further 
margins will be removed if permanent pathology is positive without tissue rearrangement 
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that may distort the tumor cell orientation.  Therefore each step of the algorithm centers 
on establishing negative margins before closure. 
 Given the many advantages of Mohs surgery and the high safety profile that has 
been found, we believe that Mohs surgery should be the first line treatment when 
feasible.  After clinical assessment of the tumor, all patients who are candidates for Mohs 
surgery should undergo this method of treatment where margins can be visualized in real 
time.  Ultimately the decision of whether or not a patient will undergo Mohs surgery will 
be made on a case by case basis depending on the patient, location of the tumor with 
respect to the cutaneous tissue, and the experience of available clinicians.  If Mohs 
surgery fails to achieve complete resection because the lesion extends into deep structures 
or the patient cannot tolerate further surgery under local anesthesia, the patient may be 
referred for surgical excision. 
 Patients for whom Mohs surgery is not feasible should undergo surgical resection 
of the tumor followed by temporary wound closure until the results of permanent 
pathology are known.  As mentioned above, this will prevent rearrangement before full 
eradication of tumor cells.  If pathology is found to be negative, reconstruction can 
proceed safely and without the risk of compromising any reconstructive options. 
 If positive margins are found on permanent pathology after resection, the lesion 
should be re-evaluated for Mohs surgery.  In many cases, Mohs surgery can be applied to 
regions known to exhibit positive margins in order to minimize tissue loss.  If Mohs 
surgery is not feasible, additional surgical excision should be performed.  If there is a 
concern for positive margins, the patient should once again be left with a temporary 
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dressing with closure deferred until definitive negative pathology returns.  This process 
should be repeated until permanent pathology demonstrates an absence of tumor cells.  
 Recurrent DFSP, lesions that continue to exhibit positive margins after multiple 
resections, and patients for whom complete tumor resection would cause a mutilating 
deformity require special considerations.  These patients may benefit from radiation 
therapy in the postoperative or preoperative period.  In addition, patients with the 
fibrosarcomatous high-grade variant of DFSP may require a more intensive treatment 
approach.20 
 After permanent pathology demonstrates an absence of tumor cells, reconstruction 
can be safely performed.  When margins are known to be negative flap coverage is a safe 
and cosmetically superior method of closure.  We believe that this algorithm will lead to 
systematic and successful extirpation of DFSP with a drastic reduction in recurrence rates 
as well as decreased tissue defects leading to improved cosmetic results.   
 Eighty percent of patients at our institution were treated with immediate closure 
following surgical excision of DFSP, and fifty percent of all patients underwent 
immediate closure with flaps.  A significant number of patients (40%) who underwent 
immediate closure were found to have positive margins on permanent pathology.  This 
necessitated re-opening of the previous closure for further excision of tumor cells and 
subsequent reconstruction of the defect.  Three patients found to have positive margins 
had undergone more extensive immediate reconstruction with flaps.  These findings are 
consistent with the unpredictable extent of DFSP; even patients with wide excisions have 
been found to have a high rate of positive margins.9,17  This is likely due to the infiltrating 
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nature of DFSP and projecting tumor tendrils that mimic normal tissue and are therefore 
difficult to detect macroscopically.9   
 As mentioned above, immediate reconstruction after excision of a DFSP can be 
problematic if margins are found to be positive on permanent pathology.  The first 
closure may limit subsequent reconstructive options, particularly in areas with large 
defects or around the head and neck, where reconstructive options are already limited.  
Immediate reconstruction in the context of residual tumor also poses risks for the spread 
of tumor cells.  Undermining tissue for flap reconstruction, or simply tissue re-
approximation, has the potential to open new tissue planes for tumor implantation.  
Dubay et al. reported their experience with a patient who had undergone immediate 
closure at an outside institution with bilateral rotation flaps and was found to have 
positive margins on permanent pathology.  The initial tumor was described as less than 1 
cm, and when flaps were re-resected, the tumor was found to extend through the entire 
undermined tissue plane beneath flaps, with no tumor noted in the overlying superficial 
adipose or dermal tissue.19  This observation highlights the risk of infiltration of residual 
tumor cells into the plane of dissected tissue.  It is also possible that the rearrangement of 
tissue during closure may disseminate tumor cells, making re-resection of the positive 
margin inadequate to remove all disease. 
 Achieving clear margins after the first resection of the tumor has been found to be 
critical to the prognosis of DFSP.  In a review of the current management of DFSP, 
McArthur et al. highlighted the importance of achieving local control by adequate initial 
resection because locally recurrent and neglected lesions have a propensity for deep 
fascial, muscular, and bone invasion, as well as an increased likelihood of recurrence 
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leading to metastasis.20  Arnaud et al. reviewed the outcomes of 114 patients who had 
undergone surgical treatment for DFSP with a mean follow-up time of 61 months.21  
Interestingly, the authors found that the rate of recurrence was not related to the size of 
the tumor.  Two out of 41 patients treated with wide resection for a recurrent tumor 
developed further local disease and died of metastatic fibrosarcoma, compared with none 
of the 60 patients treated with wide initial resection.  The authors concluded that accurate 
initial resection of the tumor is the most important prognostic factor for decreased 
recurrence and metastasis.  Resection with delayed closure ensures that further margins 
will be removed if permanent pathology is positive without tissue rearrangement that may 
distort the tumor cell orientation.  
 Bowne et al. confirmed the importance of initial accurate resection in a large 
retrospective analysis of patients treated for DFSP at the Memorial Sloan-Kettering 
Cancer Center.9  The authors analyzed clinicopathologic factors for disease-free survival 
in 159 patients at their institution.  Patients were separated based on whether they 
exhibited the classic form of DFSP or the fibrosarcomatous "high grade" variant.  As 
mentioned earlier, the fibrosarcomatous variant (FS-DFSP) is a much more aggressive 
tumor and carries a worse prognosis.  Like Arnaud et al., the authors found that tumor 
size, site, and depth did not correlate with increased recurrence.  However, positive or 
very close (less than 1 mm) to positive microscopic margins was a poor prognostic factor.  
Classic DFSP resected with negative microscopic margins was found to have a 
recurrence rate of 7%, while classic DFSP resected with positive microscopic margins 
was found to have a recurrence rate of 27% at five years.  The more aggressive 
fibrosarcoma variant of DFSP was found to have a recurrence rate of 28% and 100% at 
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five years with negative and positive margins, respectively.9  The authors concluded that 
incomplete resection of tumors cells was correlated with a high disease relapse rate.  
 A 2003 study by Khatri et al. further underscored the importance of adequate initial 
excision of DFSP.  In this study, recurrent lesions were found to have a propensity for 
deep fascial, muscular, and bone invasion when compared to primary lesions.8  In 
addition, there is a risk of de-differentiation of DFSP to the FS-DFSP variant, which as 
noted earlier is associated with a further increased recurrence rate and rate of metastasis.8  
Other studies have shown that metastases are usually preceded by multiple local 
recurrences after inadequate initial resection.2 
 No patients in our study experienced recurrence after treatment with surgical 
excision or Mohs surgery over an average follow-up period of 8.9 years.  This recurrence 
rate is significantly lower than the 18%-43% averages found in a literature review.2  One 
patient in our study presented with extension of disease after incomplete surgical 
excision.  As mentioned above, this was a 48 year-old female with a 10 by 11 cm DFSP 
of the scalp.  The tumor was initially excised with three centimeter margins and 
immediate closure was performed after resection with a split-thickness skin graft.  After 
permanent pathology showed positive deep margins, the patient was referred for radiation 
therapy.  She elected to pursue observation of the lesion only.  Two years later, the 
patient presented with nodules at the edge of the split thickness skin graft found to be 
recurrent DFSP.  She underwent further resection, this time with reconstruction of the 
defect with a fasciocutaneous flap from the posterior cervical muscles.  On permanent 
pathology, the tumor approached within 1 mm at the deep margins.  The patient elected 
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to pursue radiation therapy, and has experienced no further extension of disease in the 4 
years following treatment.  
 
Mohs Surgery 
 
 Mohs surgery provides a method of eradicating tumor that rests on intraoperative 
evaluation of tumor margins, without the need for deferral of closure.  During Mohs 
surgery, frozen sections are taken in real time while the patient is awake.  This offers 
several advantages over surgical excision, not the least of which is that the patient is not 
exposed to the inherent risks of prolonged general anesthesia.  The tumor is resected in a 
stepwise fashion with the understanding that further sections will be removed but that 
tissue removal will be based on the presence of tumor cells.  The processing for Mohs 
surgery involves drawing a map of the specimen and dividing this into smaller segments 
which can be frozen and color-coded with dyes in order to create a a comprehensive 
anatomic map that can be visualized histologically.  Sections are cut along the periphery 
on a continuous plane from the surface at the edge to the deepest portion of the edge, 
allowing complete visualization of the margins.22  For this reason, smaller surgical 
margins are possible with maximal preservation of unaffected healthy tissue.  In our 
study, the median margin taken during Mohs surgery was over 1cm less than the median 
margin used in surgical excision (1.17 compared to 2.5 cm).  When surgical margin was 
calculated including all subsequent resections, the difference between median margin size 
increased (1.17 compared to 3.00 cm).  This finding is not surprising given the technique 
used in Mohs surgery.  For areas of the body where generous excisional margins are not 
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practical, such as the face or extremities, this conservation of normal tissue represents a 
significant reconstructive advantage.  In addition, Mohs surgery provides real-time 
definitive information about margins without requiring subsequent procedures and 
delayed closure.   
 Mohs surgery frozen sections must be differentiated from intraoperative frozen 
sections that may be processed during surgical excision.  The role of intraoperative frozen 
sections for determining the status of margins in real time remains undefined.  
Intraoperative frozen sections are not routinely processed and analyzed with the same 
meticulous mapping technique as in Mohs surgery and therefore do not carry the same 
reliability.  In comparison to Mohs frozen sections, intraoperative frozen sections are 
processed using a standard vertical step sectioning which permits examination of a 
random number of individual sections from the excised specimen.1  Therefore the 
specimen is not comprehensively viewed by the pathologist, and a margin may be called 
falsely negative if the sections viewed by the pathologist do not contain tumor cells.  
Stojadinovic et al. compared intraoperative frozen sections to permanent pathology for 20 
patients who were treated for DFSP of the head and neck at Memorial Sloan-Kettering 
Cancer Center between 1964 and 1999.  The authors found that intraoperative frozen 
sections carried a sensitivity of 43% and a false negative rate of 57%, and concluded that 
intraoperative frozen sections do not assess resection margins accurately.23  In our case 
series, two patients were found to have positive margins on permanent pathology despite 
negative intraoperative frozen sections.  While intraoperative frozen sections may be used 
to guide resection, they are not reliable in assessing DFSP margins and should be used 
with caution when determining whether reconstruction can safely proceed.   
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 While Mohs surgery provides a more accurate analysis of margin status than 
routine intraoperative frozen sections, the Mohs technique has several shortcomings 
when compared to permanent pathology processing.  Several authors have described the 
difficulty delineating tumor borders during Mohs surgery at the periphery of frozen 
specimens where malignant cells become sparse and resemble normal fibroblasts.24  
These confounding cells are not found on paraffin sections.  In cases where the extent of 
the tumor is difficult to judge, some authors advocate taking a biopsy of an analogous 
area to serve as a control in order to differentiate the normal distribution of fibroblasts 
from tumor cells.  In addition, frozen sections in Mohs surgery do not routinely undergo 
the same immunohistologic staining that would be performed for permanent pathology 
analysis.  Immunostaining was originally demonstrated on paraffin-embedded sections, 
and the application to frozen sections is anecdotal and unproven.2  One such 
immunohistologic marker is CD 34, which is useful in differentiating DFSP from other 
fibrohistiocytic tumors.25  This stain has been incorporated into the final stages of Mohs 
surgery at some institutions in order to confirm free margins.10  Alternatively, authors 
have suggested preparing paraffin sections as a final layer for analysis after negative 
margins are found on MMS, which would allow for immunohistologic processing.26   
 Despite these concerns, the pathologic techniques used in Mohs surgery have been 
shown to provide an excellent cure rate.  Although data is limited compared to surgical 
excision, very few recurrences have been reported.  In one of the largest trails to date, 
Ratner et al. reviewed the records of 50 patients with DFSP treated with Mohs surgery.    
With an average follow up time of 4.8 years, the authors observed only one patient who 
developed a local recurrence.13  Wacker et. al performed a literature review pooling 303 
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patients treated with Mohs surgery for DFSP.  In this group, only six patients developed 
recurrent disease, resulting in a 2% recurrence rate.26  Lower rates have been observed 
using modified Mohs surgery techniques, such as that proposed by Breuninger and 
Schaumburg-Lever, where paraffin-embedded sections are employed as well as 
immunohistochemistry for CD34.27,28   
 Exclusion criteria for treatment of DFSP with Mohs surgery varies by the 
institution and resources available (Table 3.)  Tumors that are large, recurrent, previously 
irradiated, or aggressive are more likely to be found to be unresectable by Mohs surgery, 
however these same risk factors may also be indications for Mohs surgery.29  Recurrent 
lesions provide additional challenges to Mohs surgeons because of tissue distortion and 
scarring.  In very large lesions, there is an increased risk of extension of the tumor 
beyond the subcutis into vital structures such as bone, where paraffin sections may be 
necessary for accurate pathology.  As Mohs surgery is usually performed under local 
anesthesia, larger lesions may limit the use of Mohs surgery when lidocaine toxicity is a 
concern.  For lesions with these characteristics, surgical excision may be the treatment of 
choice.   
 
 
 
 
 
 
   
 
 
 
 
 
Table 3. Exclusion Criteria for Mohs Surgery 
Patient preference 
Needle phobia 
Large lesions (criteria dependent on the institution) 
Lesion exceeds limits of local anesthesia 
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Mohs surgery may play a role in subsequent stages of tumor resection for lesions that 
were initially not amenable to Mohs surgery.  As mentioned in our results, one patient 
with recurrent DFSP of the forehead was initially treated with surgical resection.  She 
was referred for Mohs surgery when permanent pathology showed a foci of tumor cells 
extending into the upper eyelid.  Mohs surgery permitted mapping of the remaining 
tumor and removal with minimal tissue loss. 
 Occasionally Mohs surgery is terminated intraoperatively when the margins are still 
known to be positive if the lesion extends into deep structures that may not be further 
removed under local anesthesia.28  In our study three patients continued to exhibit 
positive margins after four stages of Mohs surgery.  All of the patients presented with 
DFSP in a functionally or cosmetically important region - the anterior scalp along the 
hairline border, the clavicle, and the anterior foot with tumor extension into the anterior 
tendons.  Due to the size of the defects (7.2 by 5.7 cm, 6.5 by 5.5cm, and 5 by 5 cm, 
respectively) a second stage procedure under general anesthesia was planned for 
reconstruction, and further surgical resection was performed at that time.  Although full 
resection was not possible with Mohs surgery, initial resection with Mohs surgery served 
to the isolate the extension of tumor cells, and allowed for more focused surgical 
resection in areas where tissue conservation was critical.   
 
Surgical Excision with Delayed Closure  
 
 Mohs-trained surgeons and specialized Mohs teams are less available than 
traditional surgical teams, and thus expense and resources may limit when Mohs surgery 
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can be performed.  When Mohs surgery is not feasible because of logistical concerns or 
tumor characteristics, surgical re-excision of tumor positive areas until tumor-free 
margins are obtained has been found to ensure a high cure rate.7  Delayed closure has 
been advocated by several authors as a method of ensuring complete tumor extirpation 
before reconstruction.29,30  Sondak et al. describe a staged approach to surgery where the 
wound is covered with allograft with planned re-operation seven days later if primary 
closure without undermining is not possible.  Using this approach, the authors found no 
recurrences among 45 patients.29 
 Full tumor resection with delayed closure has a high rate of cure even among these 
patients who are most at risk for recurrence.  Thiele et al. analyzed the long term 
outcomes of seven patients who presented to their institution with recurrent DFSP of the 
head and neck.31  Patients in the analysis were included only if at least one attempt to 
surgically cure the patient had been performed previously at a different institution, and 
patients had on average undergone surgery three times previously.  One patient included 
in the study had undergone 12 operations for recurrent DFSP of the infraorbital region.  
As discussed earlier, recurrent lesions have been found to be significantly larger with a 
higher propensity for bone involvement, future recurrence, and metastasis.8  In addition, 
DFSP of the head and neck have a notoriously high rate of recurrence, ranging between 
50 and 80%.2,31  These patients, therefore, represent a group that is extremely at risk for 
recurrence and disease progression.  All patients in the study by Thiele et al. were treated 
with surgical excision of the tumor with a minimum 1 cm free surgical margin, followed 
by coverage with artificial skin until definite histopathologic examination confirmed free 
surgical margins.  Six out of seven patients required at least two operations in order to 
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achieve complete free margins.  After this treatment method, at five years the patient 
survival rate was 100%, and only one patient had experienced recurrence.  This study 
shows that staged surgical resection with delayed closure can minimize recurrence rates 
even in the most challenging of cases. 
 In the interim between staged excisions, allograft is usually used as a temporary 
dressing.  However, it is likely that other methods of temporary dressing may be equally 
if not more successful.  Pearson and Amsberry reported their experience using a negative 
pressure wound dressing (Wound-Vac®) as a temporary dressing while waiting for final 
permanent pathology results after wide excision of a DFSP.4  The authors found that the 
negative pressure wound dressing decreased wound care and dressing changes as 
compared to traditional dressings, and provided an optimal wound bed for definitive 
wound management. 
 
Reconstruction 
 
 Due to the infiltrating nature of DFSP, tumor resection often results in large 
defects that require extensive undermining or reconstruction.  In a retrospective study of 
218 patients treated for DFSP, Fiore et al. found that one-third of patients required 
reconstructive surgery, and the need for reconstruction was more frequent in patients with 
tumors of the head and neck.6  The NCCN guidelines promote the use of a STSG to 
monitor for recurrence when positive margins may be in question or when the clinician 
deems this appropriate.  Historically, STSG have been used in closure for DFSP under 
the auspices that they would allow for better monitoring of local recurrence.   For years 
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surgeons employed STSG to obtain closure after melanoma resection.  This was done out 
of a concern that flap repair would camouflage early local recurrences in the bed of 
excision, and possibly increase the risk for local recurrence as a result of additional 
dissection. 31  However, it has not been shown that skin grafts increase the sensitivity of 
monitoring for recurrence.   In addition, STSG provide poor aesthetic outcomes, with 
problems such as color mismatch, contour deformity, wound contracture, and 
disfigurement. 32  Cassileth et. al. surveyed 176 patients who had undergone Melanoma 
resection followed by grafted closure.  The authors found that the deep scar depression 
from skin grafting led to increased psychological distress among patients following 
surgery. 33  Just as for melanoma, there is little evidence that STSG allows for improved 
surveillance of DFSP recurrence.  Flap coverage has been shown to be safe, and provides 
significant advantages such as a superior cosmetic results, earlier post-operative 
ambulation and and faster mobilization when compared to skin grafts, resulting in a 
decreased length of hospital stay. 31,33  Given that complete removal of tumor cells is 
considered curative for DFSP2 we believe that flap closure should be employed when 
possible after negative margins are demonstrated by permanent pathology.   
 
Adjuvant Chemotherapy  
 
Although fewer than 5% of patients with DFSP develop metastatic sarcoma, the 
prognosis of such patients is poor, with survival ranging from one to 48 months. 2,20,34,35  
Metastasis predominantly occur through a hematogenous route to the lungs, but have also 
been reported in the brain, bone, and peritracheal area.2  Chemotherapy that has 
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traditionally be used to treat sarcomas has not been found to be effective in treating 
DFSP. 7  Imatinib mesylate, (Gleevec; Novartis Pharmaceuticals, Basel, Switzerland) is a 
tyrosine kinase inhibitor that has proven clinical activity against chronic myelogenous 
leukemia expressing bcr-abl and gastrointestinal stromal tumors expressing c-kit. 35,36  As 
mentioned earlier, the pathology of DFSP is thought to result from a translocation 
resulting in production of a fusion protein that causing continuous stimulation of platelet 
PDGF protein tyrosine kinase, resulting in increased production of PDGF and abnormal 
cellular proliferation.7 (Figure 4)  Imatinib, which selectively inhibits PDGF alpha and 
beta receptors, has demonstrated activity against DFSP cells in vitro and vivo. 20  Due to 
this inhibition, imatinib has the potential to serve as a targeted treatment modality for 
DFSP. 
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Figure 4.  The pathology of Dermatofibrosarcoma protuberans results from the 
chromosomal translocation t(17;22) resulting in fusion of the COL1A1 and PDGFB 
genes.    Protein product from this fusion causes continuous activation of the PDGFB 
receptor and oncogenic intracellular signaling.  Imatinib inhibits PDFGR protein-tyrosine 
kinase.  From McArthur G. Molecularly targeted treatment for dermatofibrosarcoma 
protuberans.  Semin Oncol 2004 ; 31 (2 Suppl 6):30-6.   Reprinted with permission from 
Elsevier. 20 
 
 Labropoulos and Fletcher reported one of the first successes of imatinib therapy in 
the treatment of DFSP in 2005.37  They described a 48 year-old woman with recurrent 
DFSP of the upper back.  At the time of the third recurrence, she was found to have the 
fibrosarcomatous DFSP variant with metastasis to one lymph node in her axilla.  A 
staging chest computed tomography scan showed three nodular lesions in the bilateral 
lungs, the largest measuring 8mm.  The patient was initially treated with a combination 
chemotherapy regimen protocol that was traditionally used for high-grade soft tissue 
sarcoma, which consisted of three cycles of ifosphamide with MESNA and liposomal 
doxorubicin, but was unresponsive to the regiment.  She was begun on imatinib mesylate 
therapy, and within one month there was a dramatic decrease in tumor size on the 
patient's back, and a CT of the chest showed resolution of the three lung nodules.  The 
patient experienced minimal toxicity from imatinib and complete remission of the 
metastatic DFSP was observed at 20 months follow up.  This is one of seven published 
case reports showing successful treatment of metastatic DFSP with imatinib. 
 The largest trial in the literature thus far - the Imatinib Target Exploration 
Consortium Study B2225 -  shows promising results for 10 patients treated with 
imatinib.38   Eight of the patients were treated for locally advanced disease and two were 
treated for metastatic disease. Half of the patients with locally advanced disease 
experienced complete disappearance of measurable and assessable disease.  The other 
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half experienced a decrease of at least 50% in tumor diameter, which permitted full 
surgical resection of the tumor.  Of the two patients with metastatic disease, one 
experienced a partial response that lasted seven months.  The other patient experienced 
no change in tumor size and died on day 32 of the trial.  This was the only patient in the 
study found to lack the t(17;22) abnormality.  It seems that patients may have differential 
sensitivity to therapy, perhaps based on tumor expression of t(17;22.)38,20  
 Imatinib is currently approved for treatment of adult patients with unresectable, 
recurrent, and/or metastatic DFSP who are not eligible for surgery.  It is possible that the 
role of imatinib may be expanded to include preoperative debulking of large tumors 
located in areas of cosmetic and functional importance.  Mehrany et al. published a recent 
case report describing the use of imatinib as a neoadjuvant chemotherapeutic agent for 
tumor shrinkage in the case of unresectable DFSP.  The authors followed a 46 year-old 
patient with a large DFSP of the left cheek who underwent therapy with imatinib before 
surgical resection of the lesion.35  At the time of diagnosis, computed tomography and 
magnetic resonance imaging scans showed the tumor abutting and possibly invading 
muscles of facial expression.  After initiation of therapy, the patient experienced a 
dramatic decrease in tumor size with concurrent softening of the tumor.  By the 20th 
month of therapy, the tumor was small enough to be fully resected by Mohs surgery.  
Because of the decrease in tumor size, the patient maintained nearly full function of the 
muscles of facial expression.  At eighteen months he has had no disease recurrence. 
 However, some pathologists have expressed concern that treatment with imatinib 
mesylate could complicate pathologic interpretation of lesions.  In a letter to the editor, 
Ortiz et al. postulated that imatinib could create noncontinuous islands of tumor, giving 
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the false impression of clear margins after Mohs surgery.39  Because of this risk, the 
authors proposed that imatinib be used as in the postoperative period rather than as a 
neoadjuvant therapy.39  While larger, case controlled trials are needed to further 
understand the risks of imatinib, it is clear that this chemotherapeutic shows enormous 
potential for certain subgroups of patients with DFSP.  
 
Radiation Therapy 
 
 Several authors have suggested a role for radiation therapy as an adjuvant to 
surgery in the treatment of DFSP for lesions with close or positive margins.18,40  Ballo et 
al. reviewed 19 patients at the University of Texas M. D. Anderson Cancer Center who 
received radiation therapy with doses of 50-60 Gy for DFSP.40  Ten of the patients 
presented with recurrent disease.  Seventeen patients received postoperative radiation 
therapy, six with positive microscopic margins following surgery and 10 with negative 
microscopic margins and a surgical margin of less than 3 cm.   The two patients that 
received preoperative radiation therapy achieved complete surgical resection.  Only one 
patient developed recurrence during the median study follow-up of six years.  This 
patient’s course was complicated by prolonged wound healing which delayed radiation 
therapy, and regrowth of the disease before treatment was started.   
 A later study by Suit et al. at the Massachusetts General Hospital assessed the 
results of radiation therapy as a primary treatment for lesions not amenable to surgery.41  
Although the number of patients was small (n=3), local control was achieved and patients 
had no evidence of disease at 106, 85, and 108 months.  These patients presented with 
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moderately sized tumors ranging from 3 by 5cm to 8.5 by 4.5 cm, on the upper anterior 
chest wall, the scalp behind the hairline, and the chin.  In addition, all patients had 
excellent cosmetic results with the exception of atrophy and telangectasia in one 
patient.41   
 While promising, the data for radiation therapy is limited, and therapy may not be 
without risks.   There are reports that radiation may induce new or high-grade tumors.42  
The National Comprehensive Cancer Network suggests consideration of radiation 
therapy for metastatic lesions or in cases of recurrent disease where unacceptable 
functional or cosmetic outcomes will occur.     
 In conclusion, we believe that the management of DFSP should be focused on 
establishment of negative pathology before reconstruction.  Given our experience, we 
present a novel algorithm that minimizes the risk of residual microscopic disease.  In 
addition to decreasing local and distant DFSP recurrence, we believe this algorithm will 
provide optimal aesthetic results for patients. 
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